VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

TCT 2021 | Infusion of CD30 CAR T-cells following AuHCT in patients with lymphoma

Marcie Riches, MD, MS, The University of North Carolina at Chapel Hill, Chapel Hill, NC, discusses the results of a Phase I multicenter study evaluating the use of CD30 CAR T-cell infusion following autologous transplant (AuHCT) in patients with relapsed/refractory lymphoma. The results of this study demonstrate CD30 CAR-T infusion is safe and well-tolerated, with a 1-year progression-free survival of 79% in patients with Hodgkin lymphoma. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter